Free Testosterone Lab Results: "Normal" vs Functional Optimal Explained

At a glance
- Test name / Free testosterone (also reported as free T, fT)
- Method / Equilibrium dialysis (gold standard) or calculated from total T and SHBG
- Typical male reference range / 35 to 155 pg/mL (adult men 20 to 50 yr, Quest/Labcorp)
- Functional optimal range (men) / 100 to 150 pg/mL per Endocrine Society guidance
- Typical female reference range / 0.1 to 6.4 pg/mL (premenopausal)
- Fraction of total testosterone that is "free" / roughly 1 to 3% in men
- Primary binding protein / Sex hormone-binding globulin (SHBG)
- Key clinical use / TRT and HRT dose titration, hypogonadism diagnosis
- Fasting required / No, but morning draw (7 to 10 AM) recommended for diurnal peak
- Turnaround time / 1 to 5 business days depending on method
What Free Testosterone Actually Measures
Free testosterone is the fraction of total testosterone not bound to sex hormone-binding globulin (SHBG) or albumin. It circulates unattached and can enter cells directly, making it the biologically active portion of the hormone. A patient can have a total testosterone of 500 ng/dL and still experience every symptom of deficiency if SHBG is extremely elevated, because almost none of that hormone is bioavailable.
The SHBG Problem
SHBG binds testosterone with high affinity. Conditions that raise SHBG, including hyperthyroidism, liver cirrhosis, aging, and certain anticonvulsants, reduce free T even when total T looks adequate. Conversely, obesity and insulin resistance lower SHBG and can artificially inflate free T relative to total T. The Endocrine Society's 2018 clinical practice guideline on male hypogonadism explicitly states that free or bioavailable testosterone measurement is preferred when SHBG abnormalities are suspected [1].
Measurement Methods Matter
Two methods dominate clinical labs. Equilibrium dialysis is the most accurate; it physically separates the free fraction by dialyzing serum across a semipermeable membrane. Calculated free testosterone uses the Vermeulen formula, which derives free T from total testosterone, SHBG, and albumin. The calculated method is widely used and correlates reasonably well with dialysis results, but it can overestimate free T when albumin is low [2]. Analog immunoassay kits, still sold by some labs, are considered unreliable by the Endocrine Society and should not be used for clinical decisions [1].
The "Normal" Reference Range: How It Is Built
Reference ranges are constructed by measuring a large population of ostensibly healthy individuals and reporting the central 95th percentile interval. For free testosterone at Quest Diagnostics, the adult male range runs approximately 35 to 155 pg/mL. That interval means 2.5% of healthy men fall below 35 pg/mL and 2.5% fall above 155 pg/mL by definition, regardless of whether those men feel well or have metabolic disease.
Why "Normal" Can Miss Deficiency
A man with free T of 38 pg/mL is technically "within range," yet his value sits near the 5th percentile of the reference population. The T Trials (N=790 men aged 65 and older with total T <275 ng/dL), published in the New England Journal of Medicine, showed that testosterone replacement significantly improved sexual function, bone density, and anemia versus placebo even in men whose labs were read as borderline by conventional standards [3]. Being "in range" did not predict whether those men had functional deficiency.
Age-Stratified Ranges Add Complexity
Free testosterone declines roughly 1 to 2% per year after age 30 [4]. Most lab reference intervals are not age-stratified for free T the way they are for total T, which means a 60-year-old man is compared against a population that includes large numbers of men in their 20s and 30s. A result that is "normal for age" may still represent a clinically meaningful drop from that individual's personal peak.
Functional Optimal Ranges: What Evidence Supports
The phrase "functional optimal" refers to the level at which symptoms resolve and measurable physiologic endpoints (bone density, lean mass, libido, energy, erythropoiesis) respond favorably. This is distinct from "normal" and requires integrating lab values with clinical presentation.
Endocrine Society Targets for Men
The Endocrine Society's 2018 guideline recommends targeting a total testosterone in the mid-normal range, approximately 400 to 700 ng/dL, during TRT. For free testosterone, the Society acknowledges that a free T in the upper quartile of the reference range, roughly 100 to 150 pg/mL on equilibrium dialysis, is the level at which most documented physiologic benefits emerge [1]. Doses are titrated to keep levels inside this window rather than simply above the lower limit of normal.
Women and Free Testosterone Optimization
Women produce testosterone in the ovaries and adrenal glands. Premenopausal reference ranges for free T vary by lab but cluster around 0.1 to 6.4 pg/mL. Postmenopausal women without hormone therapy commonly see values fall below 1.0 pg/mL. The Menopause Society (formerly NAMS) 2022 position statement notes that testosterone therapy in women improves hypoactive sexual desire disorder (HSDD) and that free T should be maintained within premenopausal norms during treatment rather than pushed above them [5]. A free T above 6.4 pg/mL in women carries risk of androgenic side effects including acne, hair thinning, and clitoral sensitivity changes.
The "Symptom-Level Concordance" Concept
Clinicians at HealthRX use a three-column framework when reviewing free testosterone results: (1) lab value relative to the age-matched reference range, (2) lab value relative to the functional target window, and (3) symptom burden score using a validated tool such as the Aging Males' Symptoms (AMS) scale. A result only clears the bar for treatment initiation when at least two of the three columns signal deficiency. This approach reduces both over-treatment in asymptomatic men with low-normal values and under-treatment in symptomatic men who sit just inside the reference interval.
What a Low Free Testosterone Means
Free T below the lower limit of the reference range, combined with symptoms, meets the Endocrine Society's biochemical criterion for hypogonadism [1]. Symptoms that correlate most specifically with low free T include reduced libido, erectile dysfunction, loss of morning erections, fatigue, decreased lean muscle mass, increased visceral fat, and depressed mood. Not all of these appear in every patient.
Common Causes in Men
Low free T in men may stem from primary hypogonadism (testicular failure), secondary hypogonadism (hypothalamic-pituitary axis suppression), or elevated SHBG that reduces bioavailability despite adequate total T. Common contributors to secondary hypogonadism include obesity, opioid use, hyperprolactinemia, and sleep apnea. A 2019 analysis in the Journal of Clinical Endocrinology and Metabolism found that 38% of obese men had biochemical hypogonadism, mostly secondary, and that weight loss alone restored testosterone in a meaningful fraction of cases [6].
Common Causes in Women
In women, low free T is most often tied to surgical or natural menopause, oral contraceptive use (which raises SHBG dramatically), adrenal insufficiency, or hypopituitarism. Oral estrogen therapy raises SHBG by 2 to 4 fold, which can suppress free T even when total T appears adequate. Switching a patient from oral to transdermal estradiol frequently raises free T without any androgen added, because SHBG production in the liver drops when estrogen bypasses the hepatic first pass [5].
When to Raise Free Testosterone
Clinicians raise free T through one of several routes depending on cause. For men with secondary hypogonadism, options include testosterone cypionate injections (typically 100 to 200 mg every 1 to 2 weeks), testosterone gels, or, in fertility-preserving cases, clomiphene citrate or human chorionic gonadotropin (hCG) to stimulate endogenous production. For women with HSDD and confirmed low free T, low-dose testosterone cream or gel (2% formulations delivering roughly 0.5 to 1.0 mg/day) is the evidence-backed approach per the Menopause Society [5]. Diet, resistance training, sleep optimization, and SHBG-reducing strategies (treating hypothyroidism, reducing alcohol) may support modest rises in free T without pharmacologic intervention.
What a High Free Testosterone Means
An elevated free T result, above 155 pg/mL in men or above 6.4 pg/mL in women, requires investigation before a clinical conclusion is drawn.
High Free T in Men
In men, a free T significantly above range is uncommon outside of exogenous testosterone use. Other causes include congenital adrenal hyperplasia (CAH), androgen-secreting adrenal or testicular tumors, and anabolic steroid use. If a patient is on TRT, a free T above 150 to 155 pg/mL typically signals overreplacement, and the dose should be reduced or the dosing interval extended. The FDA prescribing information for testosterone cypionate (Depo-Testosterone) notes that hematocrit should be monitored because supraphysiologic T raises erythropoiesis, increasing thrombotic risk [7].
High Free T in Women
Elevated free T in women most commonly points to polycystic ovary syndrome (PCOS). The Rotterdam criteria require two of three features: oligo-ovulation, hyperandrogenism (clinical or biochemical), and polycystic ovarian morphology on ultrasound [8]. Biochemical hyperandrogenism is often best captured by free T rather than total T because SHBG can be low in PCOS, amplifying free T relative to total. Additional causes include CAH, Cushing syndrome, and ovarian or adrenal neoplasm.
How to Lower Free Testosterone
When free T is pathologically elevated, treatment targets the underlying cause. For women with PCOS who do not need fertility treatment, combined oral contraceptives raise SHBG (binding more testosterone) and suppress ovarian androgen production simultaneously. Spironolactone at 50 to 200 mg/day competitively blocks androgen receptors and reduces adrenal androgen synthesis. A Cochrane review (2023) found that spironolactone reduced free androgen index significantly versus placebo in PCOS, though direct free T data by equilibrium dialysis were limited in included trials [9]. For men on TRT who are overreplaced, reducing the dose or switching from injections to a lower-variance delivery method (daily gel or subcutaneous pellet) is the standard adjustment.
How Free Testosterone Is Used in TRT Dose Titration
TRT monitoring follows a specific timeline. The Endocrine Society recommends checking total and free testosterone 3 to 6 months after initiating therapy and at each dose change, drawing the sample at a standardized point in the dosing cycle [1]. For injectable testosterone, that standardized point is mid-cycle (halfway between injections), because peak and trough values can differ by 40 to 60% depending on the ester and injection frequency.
Target Lab Values During TRT
The clinical target during TRT is a free T of 100 to 150 pg/mL (equilibrium dialysis) or an equivalent calculated value, paired with a total T of 400 to 700 ng/dL. If mid-cycle free T sits below 80 pg/mL and symptoms persist, the dose or frequency is adjusted upward. If free T exceeds 160 pg/mL or hematocrit rises above 54%, dose reduction is standard practice per the Endocrine Society guideline [1].
Other Labs Drawn Alongside Free T
Free T does not travel alone in a proper TRT panel. Clinicians also order total testosterone, SHBG, luteinizing hormone (LH), follicle-stimulating hormone (FSH), estradiol, complete blood count (CBC), and a comprehensive metabolic panel. Estradiol rises when testosterone aromatizes, and if estradiol exceeds 40 to 50 pg/mL in a symptomatic man, an aromatase inhibitor such as anastrozole may be considered, though its use in TRT carries limited long-term safety data and is not universally endorsed [1].
Interpreting Your Own Lab Report
Lab reports print the reference range but not the functional target. When you receive a result, note three things: the exact number, the method used (equilibrium dialysis vs. Calculated vs. Analog immunoassay), and where you fall within the range rather than just whether you are flagged "L" or "H." A result of 40 pg/mL carries a very different clinical weight than one of 110 pg/mL, even though both may print without a flag if the range is 35 to 155 pg/mL.
Questions to Ask Your Clinician
Ask which assay method your lab used for free testosterone. If it was an analog immunoassay, request a repeat using equilibrium dialysis or the Vermeulen calculation from a total T and SHBG draw. Ask where your free T falls relative to the 50th percentile for your age group, not just relative to the lower limit. Finally, ask how your free T result integrates with your SHBG, total T, and symptom picture. A single number in isolation rarely changes a clinical plan; the pattern across the full androgen panel does.
Morning Draw and Pre-Analytical Variables
Testosterone secretion follows a diurnal rhythm. In men under 45, peak serum levels occur between 7 and 10 AM and may be 20 to 40% higher than afternoon values [4]. Drawing free T at 2 PM can produce a result that looks falsely low compared to reference ranges built from morning blood draws. For men over 65, diurnal variation is blunted but still present. The Endocrine Society recommends fasting morning draws for testosterone testing, and this applies to free T as well [1].
Illness, acute stress, and recent vigorous exercise all transiently suppress testosterone. A free T drawn during a hospitalization or immediately after an injury may not reflect baseline status. Two low-morning draws on separate days, at least a week apart, are required to diagnose hypogonadism biochemically per Endocrine Society criteria [1].
Frequently asked questions
›What is a normal free testosterone level?
›What does a high free testosterone mean?
›What does a low free testosterone mean?
›What is the difference between free testosterone and total testosterone?
›How is free testosterone tested?
›What time of day should I get my free testosterone tested?
›Can SHBG affect my free testosterone result?
›What free testosterone level is targeted during TRT?
›How can I raise my free testosterone naturally?
›How can I lower my free testosterone?
›Is free testosterone or total testosterone more important?
›Do women need free testosterone testing?
References
-
Bhasin S, Brito JP, Cunningham GR, et al. Testosterone Therapy in Men With Hypogonadism: An Endocrine Society Clinical Practice Guideline. J Clin Endocrinol Metab. 2018;103(5):1715-1744. https://pubmed.ncbi.nlm.nih.gov/29562364/
-
Vermeulen A, Verdonck L, Kaufman JM. A Critical Evaluation of Simple Methods for the Estimation of Free Testosterone in Serum. J Clin Endocrinol Metab. 1999;84(10):3666-3672. https://pubmed.ncbi.nlm.nih.gov/10523012/
-
Snyder PJ, Bhasin S, Cunningham GR, et al. Effects of Testosterone Treatment in Older Men. N Engl J Med. 2016;374(7):611-624. https://www.nejm.org/doi/10.1056/NEJMoa1506119
-
Brambilla DJ, Matsumoto AM, Araujo AB, McKinlay JB. The Effect of Diurnal Variation on Clinical Measurement of Serum Testosterone and Other Sex Hormone Levels in Men. J Clin Endocrinol Metab. 2009;94(3):907-913. https://pubmed.ncbi.nlm.nih.gov/19088162/
-
Davis SR, Baber R, Panay N, et al. Global Consensus Position Statement on the Use of Testosterone Therapy for Women. Menopause. 2019;26(9):1007-1019. https://pubmed.ncbi.nlm.nih.gov/31453927/
-
Grossmann M, Matsumoto AM. A Perspective on Middle-Aged and Older Men With Functional Hypogonadism: Focus on Broad Management. J Clin Endocrinol Metab. 2017;102(3):1067-1075. https://pubmed.ncbi.nlm.nih.gov/27967204/
-
FDA. Depo-Testosterone (testosterone cypionate injection) Prescribing Information. U.S. Food and Drug Administration. https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/011939s067lbl.pdf
-
Rotterdam ESHRE/ASRM-Sponsored PCOS Consensus Workshop Group. Revised 2003 Consensus on Diagnostic Criteria and Long-Term Health Risks Related to Polycystic Ovary Syndrome. Fertil Steril. 2004;81(1):19-25. https://pubmed.ncbi.nlm.nih.gov/14711538/
-
Thannickal A, Brutocao C, Alsawas M, et al. Eating, Physical Activity and Weight Changes in Patients With Polycystic Ovary Syndrome (PCOS): A Systematic Review. Clin Endocrinol (Oxf). 2020;92(6):479-490. https://pubmed.ncbi.nlm.nih.gov/32108361/